Medical and Physiological Benefits of Reduced Sitting

Turku University Hospital64 enrolled

Overview

The most important objective of this randomized controlled trial in subjects with increased cardiovascular and metabolic risk factors is to investigate whether only reduced daily sitting improves human cardiovascular and metabolic health during a six-month intervention. It is hypothesized and expected that only reduced sitting, without formal physical activity or exercise training, affects favorably cardiovascular and metabolic health.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

SINGLE

Enrollment

Conditions

Metabolic Syndrome Physical Activity Insulin Resistance Cardiovascular Diseases

Interventions

Reduced sittingBEHAVIORAL

Subjects are guided to limit their sitting time during the day for 1 hour/day, by adding light activity with the help of an activity monitor. Subjects are not encouraged to increase their moderate to vigorous physical activity levels.

Eligibility

Sex: ALLMin age: 40 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Physically inactive (less than 120 minutes of moderate intensity exercise per week measured by the activity monitor during run-in) * Sitting time ≥ 10 h /day (measured by the activity monitor during run-in) * BMI 25-40 * Blood pressure \< 160/100 mmHg * Fasting plasma glucose \< 7.0 mmol/l * Fulfills the criteria of the metabolic syndrome according to Alberti et al 2009 Exclusion Criteria: * History of a cardiac event * Insulin or medically treated diabetes * Any chronic disease or condition that could create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of study results * Presence of ferromagnetic objects that would make MR imaging contraindicated * Abundant use of alcohol * Use of narcotics * Smoking of tobacco or consuming snuff tobacco * Diagnosed depressive or bipolar disorder * Previous PET imaging or considerable exposure to radiation

Locations (1)

Turku PET Centre

Turku, Finland

Outcomes

Primary Outcomes

The change in whole-body insulin sensitivity

M-value during the hyperinsulinemic euglycemic clamp

Time frame: The change from baseline to 6 months

The change in skeletal muscle insulin-stimulated glucose uptake

Glucose uptake in the femoral muscles will be measured by positron emission tomography (PET) with \[18F\]-labelled fluoro-deoxy-glucose (FDG) tracer during hyperinsulinemic euglycemic clamp

Time frame: The change from baseline to 6 months

Secondary Outcomes

daily sitting hours

Accelerometry data will be collected during the whole intervention period by a triaxial hip-mounted accelerometer

Time frame: through study completion, an average of 6 months

daily hours spent physically active

Accelerometry data will be collected during the whole intervention period by a triaxial hip-mounted accelerometer

Time frame: through study completion, an average of 6 months

The change in liver adiposity

Liver fat content will be assessed using magnetic resonance spectroscopy (MRS)

Time frame: The change from baseline to 6 months

The change in maximal oxygen uptake

Maximal oxygen uptake (VO2peak) will be determined by cycle ergometry with direct respiratory measurements. Exercise intensity will be started at 50 W and the intensity will be increased by 25 W at every two minutes until the criteria used to establish the VO2peak are met. The criteria used to establish the VO2peak are a plateau in VO2 despite of an increase in intensity and a respiratory quotient greater than 1.1. or volitional fatigue.

Time frame: The change from baseline to 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.